Oncotelic Therapeutics, Inc. OTLC
0.01 USD 0.00 (-2.26%)
Nov 13, 2026, 10:12 AM EST
0.012 Day range 0.013
0.01 52-week range 0.10
- YTD
- -83.75%
- 1 year
- -85.56%
News
globenewswire.com Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development
globenewswire.com Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery Saran Saund to connect the emerging research approach with PDAOAI intellectual property, plans for 100 billion biological vectors, individual researcher access through Fastbot/Membot and an HCC case…
globenewswire.com PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026 Oncotelic's AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS,…
globenewswire.com Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as…
globenewswire.com Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) AGOURA HILLS, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in…
globenewswire.com Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle Platform SAN DIEGO, Calif. , July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB:…
globenewswire.com Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003 Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics
globenewswire.com Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026 Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic…
globenewswire.com Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the completion of key Phase 2 objectives in its joint…
globenewswire.com NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies AUSTIN, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “How Advanced Drug Delivery Could Improve Existing Cancer Treatments,”…
globenewswire.com Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands…
globenewswire.com Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003…
globenewswire.com Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75brands…
globenewswire.com TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics Deployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical…
globenewswire.com Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology,…
globenewswire.com NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market…
globenewswire.com Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands…